Riccardo Dalla-Favera, MD

Academic Appointments

  • Percy and Joanne Uris Professor of Clinical Medicine
  • Professor of Pathology & Cell Biology
  • Professor of Microbiology and Immunology (in the Institute for Cancer Genetis and the Herbert Irving Comprehensive Cancer Center)

Current Administrative Positions

  • Director, Institute for Cancer Genetics
Riccardo Dalla-Favera, MD

Email: rd10@cumc.columbia.edu

The research program in the Dalla-Favera laboratory is aimed at the identification of the molecular pathogenesis of human B cell malignancies. Functional and structural genomic approaches are used toward the identification of the genetic lesions leading to the transformation of B lymphocytes. The genomic landscape of the tumors is then recapitulated in genetically modified mice in order to construct models for pre-clinical testing of science-based new therapeutic modalities.

Departments and Divisions

  • Department of Genetics & Development
  • Department of Microbiology & Immunology
  • Department of Pathology & Cell Biology

Centers / Institutes / Programs

  • Herbert Irving Comprehensive Cancer Center

NIH Grants

  • FROM PATHOGENESIS TO NEW THERAPEUTIC TARGETS IN DIFFUSE LARGE B CELL LYMPHOMA (Federal Gov)

    Aug 4 2016 - Jul 31 2023

    MOLECULAR PATHOGENESIS OF B-CELL LYMPHOMA (Private)

    Jun 1 2017 - May 31 2022

    MSK SPORE IN LYMPHOMA-(PROJECT 4: TARGETING ACETYLTRANSFERASE GENE INACTIVATION IN DIFFUSE LARGE B CELL LYMPHOMA) (Federal Gov)

    Aug 30 2016 - Jul 31 2021

    MSK SPORE IN LYMPHOMA (CAREER ENHANCEMENT PROGRAM) (Federal Gov)

    Aug 30 2016 - Jul 31 2021

    NON-CODING REGULATORY MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA (Private)

    Jul 1 2018 - Jun 30 2020

    DNA DOUBLE-STRAND BREAK REPAIR, CHROMOSOMES TRANSLOCATIONS AND CANCER (Federal Gov)

    Apr 1 2014 - Mar 31 2020

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    ROLE OF MEF2B MUTATIONS IN LYMPHOMAGENESIS (Federal Gov)

    May 15 2014 - Apr 30 2019

    ROLE OF MEF2B MUTATIONS IN LYMPHOMAGENESIS (Federal Gov)

    May 15 2014 - Apr 30 2019

    ROLE OF MEF2B MUTATIONS IN LYMPHOMAGENESIS (Federal Gov)

    May 15 2014 - Apr 30 2019

    DNA DOUBLE-STRAND BREAD REPAIR, CHROMOSOME TRANSLOCATIONS AND CANCER (Federal Gov)

    Apr 1 2014 - Mar 31 2019

    DNA DOUBLE-STRAND BREAD REPAIR, CHROMOSOME TRANSLOCATIONS AND CANCER (Federal Gov)

    Apr 1 2014 - Mar 31 2019

    CD58/CD1 TARGETED CANCER IMMUNE THERAPY (Private)

    Dec 6 2017 - Dec 5 2018

    REPOSITIONING THERAPEUTIC PRINCIPLES FOR DIFFUSE LARGE B CELL LYMPHOMAS (Federal Gov)

    Aug 1 2017 - Jul 31 2018

    THE ROLE OF NOTCH1 IN THE PATHOGENESIS OF CLL (Federal Gov)

    Apr 1 2013 - Mar 31 2018

    THE ROLE OF NOTCH1 IN THE PATHOGENESIS OF CLL (Federal Gov)

    Apr 1 2013 - Mar 31 2018

    ROLE OF ACETYLTRANSFERASE GENE INACTIVATION IN FOLLICULAR LYMPHOMA PATHOGENESIS (Federal Gov)

    Apr 1 2012 - Mar 31 2017

    ROLE OF ACETYLTRANSFERASE GENE INACTIVATION IN FOLLICULAR LYMPHOMA PATHOGENESIS (Federal Gov)

    Apr 1 2012 - Mar 31 2017

    IDENTIFYING NEW DRUGS FOR DLBCL TREATMENT (Private)

    Jul 1 2013 - Jun 30 2016

    ROLE OF MEF2B MUTATIONS IN LYMPHOMAGENESIS (Federal Gov)

    Sep 1 2014 - Aug 31 2015

    EXOME SEQUENCING OF HAIRY CELL LEUKEMIA AND CLASSICAL HODGKIN LYMPHOMA (Private)

    Dec 1 2010 - Nov 30 2014

    MOLECULAR DETERMINANTS OF FOLLICULAR LYMPHOMA TRANSFORMATION (Private)

    Aug 1 2013 - Jul 31 2014

    EXOME SEQUENCING IN RICHTER SYNDROME AND CHRONIC LYMPHOCYTIC LEUKEMIA (Private)

    Jul 1 2010 - Jun 30 2014

    STEWART TRUST PILOT AWARDS FOR FY12-13 (YEAR 14) (Private)

    Jul 1 2012 - Jun 30 2014

    SUBPROJECT FOR INSTITUTION # 08-8993 (Private)

    Oct 1 2008 - Sep 30 2013

    GENOMICS OF CHRONIC LYMPHOCYTIC LEUKEMIA (Private)

    Aug 1 2011 - Jul 31 2013

    WHOLE EXOME SEQUENCING OF PLASMABLASTIC LYMPHONA (PBL) PATIENTS (Private)

    Jul 24 2012 - Jul 23 2013

    AIDS ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS (Federal Gov)

    Jul 1 2007 - Jun 30 2013

    AVON FOUNDATION BREAST CANCER PROGRAM AT THE HERBERT IRVING COMPREHENSIVE CANCER CENTER OF COLUMBIA UNIVERSITY MEDICAL C (Private)

    Jan 1 2012 - Dec 31 2012

    JJPRD CU11-3319 STUDY OF JNJ-26481585 IN CREBBP MUTATED DLBC L (Private)

    Nov 10 2011 - Nov 9 2012

    SYSTEMS BIOLOGY OF TUMOR PROGRESSION AND DRUG-RESISTANCE (Federal Gov)

    Sep 30 2009 - Aug 31 2012

    STEWART TRUST PILOT AWARDS (Private)

    Jul 1 2008 - Jun 30 2012

    ROLE OF BCL-6 IN GENERAL CENTER FORMATION AND LYMPHOMAGENES (Federal Gov)

    Jul 1 2001 - Jun 30 2012

    AVON FOUNDATION BREAST CANCER PROGRAM AT THE HERBERT IRVING COMPREHENSIVE CANCER CENTER OF COLUMBIA UNIVERSITY MEDICAL C (Private)

    Jan 1 2011 - Dec 31 2011

    NATIONAL CENTER FOR MULTI-SCALE STUDY OF CELLULAR NETWORKS (Federal Gov)

    Sep 26 2005 - Jul 31 2011

    IDENTIFICATION OF NOVEL MICRORNAS EXPRESSED IN B CELLS: ROLE IN NORMAL B CELL DEVELOPMENT AND LYMPHOMAGENESIS (Private)

    Jul 1 2009 - Jun 30 2011

    NOVEL ROLE OF C-MYC IN LYMPHOMAGENESIS (Private)

    Jul 1 2008 - Jun 30 2011

    GENETIC NETWORK INFERENCE WITH COMBINATIONAL PHENOTYPES (Federal Gov)

    Jun 21 2005 - Apr 30 2011

    REGULATORY MODULES IN NORMAL AND TRANFORMED B-CELLS (Federal Gov)

    Jul 1 2005 - Mar 31 2011

    AVON FOUNDATION BREAST CANCER PROGRAM AT THE HERBERT IRVING COMPREHENSIVE CANCER CENTER OF COLUMBIA UNIVERSITY MEDICAL C (Private)

    Jan 1 2010 - Dec 31 2010

    AVON FOUNDATION BREAST CANCER PROGRAM AT THE HERBERT IRVING COMPREHENSIVE CANCER CENTER OF COLUMBIA UNIVERSITY MEDICAL C (Private)

    Jan 1 2009 - Dec 31 2010

    ROLE OF MICRO RNAS (MIRS) INVOLVED IN HEMATOLYMPHOID DIFFERE NTION AND MALIGNANCY: IDENTIFICATION OF NOVEL MIRS EXPRESSSE (Private)

    Feb 20 2009 - Dec 31 2009

    MOLECULAR TARGETS IN LYMPHOMA COA (Private)

    Oct 1 2003 - Sep 30 2009

    PILOT AWARDS FOR CANCER RESEARCH (Private)

    Dec 1 1998 - Sep 30 2008

    ROLEOF NON-CODING RNAS LEU2, MIR15A AND MIR16-1 IN THE PATH OGENESIS OF CLL (Private)

    Jul 1 2007 - Sep 30 2008

    PILOT AWARDS FOR CANCER RESEARCH (Private)

    Dec 1 1998 - Jun 30 2008

Publications

  1. Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome
    Holmes AB, Corinaldesi C, Shen Q, Kumar R, Compagno N, Wang Z, Nitzan M, Grunstein E, Pasqualucci L, Dalla-Favera R, Basso K
    J Exp Med. 2020.
    PMID: 32603407, DOI: 10.1084/jem.20200483
  2. Chronic lymphocytic leukaemia: from genetics to treatment
    Bosch F, Dalla-Favera R
    Nat Rev Clin Oncol. 2019.
    PMID: 31278397, DOI: 10.1038/s41571-019-0239-8
  3. Repurposing dasatinib for diffuse large B cell lymphoma
    Scuoppo C, Wang J, Persaud M, Mittan SK, Basso K, Pasqualucci L, Rabadan R, Inghirami G, Grandori C, Bosch F, Dalla-Favera R
    Proc Natl Acad Sci USA. 2019.
    PMID: 31383760, DOI: 10.1073/pnas.1905239116
  4. MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis
    Brescia P, Schneider C, Holmes AB, Shen Q, Hussein S, Pasqualucci L, Basso K, Dalla-Favera R
    Cancer Cell. 2018.
    PMID: 30205047, DOI: 10.1016/j.ccell.2018.08.006
  5. Genetics of diffuse large B-cell lymphoma
    Pasqualucci L, Dalla-Favera R
    Blood. 2018.
    PMID: 29666115, DOI: 10.1182/blood-2017-11-764332
  6. The molecular pathogenesis of chronic lymphocytic leukaemia
    Fabbri G, Dalla-Favera R
    Nat Rev Cancer. 2016.
    PMID: 26911189, DOI: 10.1038/nrc.2016.8
  7. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis
    Zhang J, Dominguez-Sola D, Hussein S, Lee JE, Holmes AB, Bansal M, Vlasevska S, Mo T, Tang H, Basso K, Ge K, Dalla-Favera R, Pasqualucci L
    Nat Med. 2015.
    PMID: 26366712, DOI: 10.1038/nm.3940
  8. Germinal centres and B cell lymphomagenesis
    Basso K, Dalla-Favera R
    Nat Rev Immunol. 2015.
    PMID: 25712152, DOI: 10.1038/nri3814
  9. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma
    Ying CY, Dominguez-Sola D, Fabi M, Lorenz IC, Hussein S, Bansal M, Califano A, Pasqualucci L, Basso K, Dalla-Favera R
    Nat Immunol. 2013.
    PMID: 23974956, DOI: 10.1038/ni.2688
  10. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma
    Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, Dominguez-Sola D, Pasqualucci L, Dalla-Favera R
    Cancer Cell. 2011.
    PMID: 22137796, DOI: 10.1016/j.ccr.2011.11.006
  11. Analysis of the coding genome of diffuse large B-cell lymphoma
    Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R
    Nat Genet. 2011.
    PMID: 21804550, DOI: 10.1038/ng.892
  12. Inactivating mutations of acetyltransferase genes in B-cell lymphoma
    Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK, Dalla-Favera R
    Nature. 2011.
    PMID: 21390126, DOI: 10.1038/nature09730
  13. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma
    Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q, Chadburn A, Rajewsky K, Tarakhovsky A, Pasqualucci L, Dalla-Favera R
    Cancer Cell. 2010.
    PMID: 21156281, DOI: 10.1016/j.ccr.2010.10.030
  14. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma
    Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS, Dalla-Favera R
    Science. 1993.
    PMID: 8235596, DOI: 10.1126/science.8235596
  15. Identification of reciprocal translocation sites within the c-myc oncogene and immunoglobulin mu locus in a Burkitt lymphoma
    Gelmann EP, Psallidopoulos MC, Papas TS, Dalla-Favera R
    Nature. 1983.
    PMID: 6419123, DOI: 10.1038/306799a0

For a complete list of publications, please visit PubMed.gov